Cancer Advice 2.0 (@canceradvice20) / X

Product Description

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne

I advocated for my health. Here's how. – Prevent Cancer Foundation

The HER2-low revolution in breast oncology: steps forward and emerging challenges - Eleonora Nicolò, Luca Boscolo Bielo, Giuseppe Curigliano, Paolo Tarantino, 2023

AACR 2022: YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy - Biocytogen

HER2-low breast cancers: Current insights and future directions - ScienceDirect

Integrating Trastuzumab Biosimilars and HER2-Directed Therapies into HER2-Positive Breast Cancer Management

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) - Annals

HPV and Links to Cancer City of Hope Ask the Experts

Cancer Advice 2.0 (@canceradvice20) / X

Targeted immunotherapy for HER2-low breast cancer with 17p loss

Regarding Cancer (@RegardingCancer) / X

Cancer Advice 2.0 (@canceradvice20) / X

About HER2-low metastatic breast cancer

Experienced A Recent Cancer Diagnosis? Here's Some Advice From The Cancer Community.